Tim Miller, a former BioEnterprise CEO-in-Residence, has more than 16 years of scientific research, product development and clinical operations expertise with regenerative medicine and genetic therapy start-ups Juventas Therapeutics, SironRx Therapeutics, and Copernicus Therapeutics. In May 2015, Miller merged Aboena Therapeutics, a company he founded and a developer of genetic therapies for rare diseases, with PlasmaTech Biopharmaceuticals, developer of a technology that makes blood plasma fractionation less expensive and easier to extract. As part of the merger terms, Miller became CEO of the combined public company, PlasmaTech Biopharmaceuticals. Miller holds a B.S. in Biology from John Carroll University, a M.S. in Molecular Biology from John Carroll University, and a doctorate in Pharmacology with a focus on gene therapy/cystic fibrosis from Case Western Reserve University.